Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Clinical trial NCT03974022 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03974022
- Sponsor
- Dizal Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-09
- Primary completion
- 2024-07-29
- Enrollment
- 315
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.